Kava Wiki LogoKava Wiki
FőoldalBiztonságKölcsönhatások

Gyógyszerekkel való kölcsönhatások

What laboratory studies, small human studies and case reports actually show about kava interactions.

Röviden & tömören

Kava can interact with medicines and other central nervous system depressants. Laboratory findings show several possible CYP inhibitions, but small human studies do not confirm one uniform pattern across all enzymes. Alcohol and sedatives in particular should not be self-combined; regular medication warrants individual review.

A citokróm P450 rendszer

A citokróm P450 rendszer (CYP450) egy enzimek családja a májban, amely a legtöbb gyógyszer lebontásáért felelős. Ha egy anyag gátolja ezeket az enzimeket, más anyagok lebontása lassabbá válik – ezáltal fokozódhat a hatásuk és mellékhatásaik.

Miért fontos ez?

Many medicines are metabolised by CYP enzymes. An in-vitro finding does not automatically mean clinically relevant inhibition in humans. Preparation, dose, duration and the medicine's therapeutic window determine practical relevance.

Mely enzimek gátlódnak?

Mathews et al. (2002) tested kava extract and individual kavalactones in human liver microsomes and found inhibition of several CYP enzymes. These are in-vitro findings, not clinical inhibition ratings in humans:

EnzimGátlási erősségFontos szubsztrátok (példák)
CYP1A2In-vitro findingKoffein, Theophyllin, Clozapin, Olanzapin
CYP2C9In-vitro findingWarfarin, Phenytoin, NSAID-ok (Ibuprofen)
CYP2C19In-vitro findingOmeprazol, Diazepam, Clopidogrel
CYP2D6In-vitro findingKodein, Tramadol, sok antidepresszáns
CYP3A4In-vitro findingBenzodiazepinek, sztatinok, sok antibiotikum

Klinikai jelentőség

Russmann et al. (2005) reported reduced CYP1A2 activity in chronic users of traditional aqueous kava. Gurley et al. (2005; 12 healthy volunteers, 28 days, 138 mg kavalactones/day), by contrast, found reduced CYP2E1 but no significant change in CYP1A2, CYP2D6 or CYP3A4/5. The human findings are small and preparation- and consumption-dependent, so they cannot predict every medicine interaction.

Magas kockázatú kombinációk

The following combinations should be avoided or medically reviewed in advance. Reasons differ: some involve additive CNS effects or case reports, while others have only mechanistic signals and no controlled combination trials.

⚠ Alkohol

Risiko: AVOID

Concurrent use of kava and alcohol is not recommended:

  • 1.Additive CNS effects: Drowsiness, slower reactions and impaired coordination may increase.
  • 2.Liver risk not quantified: A combined liver risk has not been quantified reliably; the combination is avoided because of this uncertainty.
  • 3.Unpredictable intensity: Product, amount, drinking pattern and individual sensitivity make effects difficult to predict.

Do not use kava and alcohol together. The main practical reason is possible additive impairment of attention, reaction and coordination; the size of any additional liver risk is not reliably established.

⚠ Benzodiazepinek és altatók

Risiko: PROFESSIONAL REVIEW

Do not combine benzodiazepines or Z-drugs with kava without medical review:

  • •Additive sedation: Drowsiness and psychomotor impairment may increase.
  • •CNS depression: Clinically relevant potentiation is possible; controlled combination trials are lacking.
  • •Interpret CYP findings: CYP3A4 inhibition was observed in vitro but not consistently confirmed in small human studies.

Esettanulmány: Almeida & Grimsley (1996) described a semicomatose state in a 54-year-old man after reported kava and alprazolam use. A single case report is a warning signal but does not establish mechanism or frequency.

⚠ Antipszichotikumok

Risiko: PROFESSIONAL REVIEW

Individual medical review is appropriate before kava use with antipsychotics:

  • •Sedation: Additive drowsiness or psychomotor impairment is possible.
  • •Case reports: Individual reports describe movement disorders; frequency and causality are unclear.
  • •CYP findings: Laboratory inhibition does not reliably predict the level of a specific medicine.

⚠ Antikoagulánsok (vérhígítók)

Risiko: PROFESSIONAL REVIEW

Warfarin, phenprocoumon and other anticoagulants require professional review because of their narrow therapeutic window:

  • •Mechanistic signal: CYP2C9 inhibition was observed in vitro; a clinical kava-warfarin interaction has not been established in controlled studies.
  • •Monitor INR: Changes in co-used products should be coordinated with the treating clinician.
  • •Bleeding risk: The baseline risk of anticoagulation makes self-testing inappropriate.

Use kava with anticoagulation only after individual medical review.

Mérsékelt kockázatú kombinációk

A következő kombinációk óvatosságot igényelnek, és csak orvosi konzultáció után alkalmazhatók. Dózismódosítás szükséges lehet.

Antidepresszánsok

Risiko: PROFESSIONAL REVIEW

SSRI-k (Fluoxetin, Sertralin, Paroxetin stb.):
  • • Pharmacokinetic interactions may occur depending on the product but are not clinically established as a class
  • • Serotonin syndrome from kava is not established as a typical clinical effect
  • • Additive drowsiness or dizziness are possible
SNRI-k (Venlafaxin, Duloxetin):
  • • Direct clinical combination data are limited
  • • Review co-medication individually rather than inferring from in-vitro CYP data
MAO-gátlók:
  • • MAO-B effects of individual kavalactones have been studied preclinically
  • • Pawa et al. (2026) found MAO-A inhibition by flavokawain A in an in-vitro enzyme assay; humans and combination with MAO inhibitors were not studied
  • • Do not self-combine with MAO inhibitors because medicine interactions can be serious
  • • Obtain medical review before use

Antikonvulzív szerek (antiepileptikumok)

Risiko: PROFESSIONAL REVIEW

Phenytoin, Carbamazepin, Valproat és más antikonvulzív szerek:

  • •Pharmacokinetics: Altered levels are possible but cannot be predicted reliably for individual combinations.
  • •CNS effects: Additive drowsiness or coordination problems are possible.
  • •Seizure control: Changes in co-used products belong under professional supervision.

Epilepszia esetén a Kava csak orvosi felügyelet mellett használható.

Parkinson-gyógyszerek

Risiko: PROFESSIONAL REVIEW

Levodopa és dopamin agonisták:

  • •Mechanism unclear: Blanket clinical dopamine antagonism by kava has not been established.
  • •Case reports: Individual reports describe worsening Parkinson symptoms; medical review is therefore needed.

With Parkinson's disease or related medication, use kava only after medical review.

Hepatotoxikus gyógyszerek

Risiko: MÉRSÉKELT

Ismert hepatotoxikus potenciállal rendelkező gyógyszerek:

  • •Paracetamol/Acetaminophen: Különösen magas dózisok esetén problémás.
  • •Sztatinok: Atorvastatin, Simvastatin stb. (CYP3A4 szubsztrátok)
  • •Methotrexat: Immunmoduláló szer májtoxicitással.
  • •Isoniazid: TBC-gyógyszer.

Additional liver risk is plausible but not quantified for every combination. Potentially hepatotoxic medication requires individual medical review.

Kölcsönhatások áttekintő táblázata

AnyagcsoportPéldákKockázatMechanizmus
AlkoholEthanolAVOIDPossible additive sedation and impaired coordination; liver risk not quantified
BenzodiazepinekDiazepam, Lorazepam, AlprazolamPROFESSIONAL REVIEWPossible additive CNS depression; one case report, no controlled combination trials
AntipszichotikumokHaloperidol, Olanzapin, ClozapinPROFESSIONAL REVIEWSedation or interactions possible; direct clinical data limited
AntikoagulánsokWarfarin, PhenprocoumonPROFESSIONAL REVIEWNo controlled kava interaction established; narrow therapeutic window
SSRI-kFluoxetin, Sertralin, ParoxetinPROFESSIONAL REVIEWPossible sedation or pharmacokinetics; no established kava serotonin syndrome
Antikonvulzív szerekPhenytoin, CarbamazepinPROFESSIONAL REVIEWPossible additive CNS effects and unpredictable pharmacokinetics
Parkinson-gyógyszerekLevodopa, dopamin agonistákPROFESSIONAL REVIEWCase reports of symptom worsening; no blanket dopamine antagonism established
SztatinokAtorvastatin, SimvastatinPROFESSIONAL REVIEWDirect clinical interaction data are lacking; review liver and medication context
OpioidokKodein, Tramadol, MorfinAVOID / REVIEWPossible additive CNS depression
KoffeinKávé, energiaitalokCAUTIONHuman CYP1A2 findings are small and inconsistent

Gyakorlati ajánlások

Ellenőrző lista Kava fogyasztása előtt

  • 1.
    Gyógyszerlista ellenőrzése

    Minden aktuális gyógyszert ellenőrizzen a kölcsönhatások szempontjából.

  • 2.
    Orvos konzultálása

    Rendszeres gyógyszerszedés esetén orvosi tanácsot kérjen Kava fogyasztása előtt.

  • 3.
    Alkohol kerülése

    Do not use kava and alcohol together. The main practical reason is possible additive impairment of attention, reaction and coordination; the size of any additional liver risk is not reliably established.

  • 4.
    Alacsony dózisban kezdeni

    Do not experiment with a self-selected lower kava dose while taking medicines; obtain professional review of the combination.

  • 5.
    Tünetek figyelése

    Figyeljen az szokatlan fáradtságra, szédülésre vagy más tünetekre.

Tovább a Biztonság fejezetben

Tanulmányok alapján

Christopher McCurdy

University of Florida College of Pharmacy

Profil megtekintése →

Hozzájárulásokkal

Ez a wiki egy kurált erőforrás, amely lektorált tanulmányok és szakértő kutatók kutatásait szintetizálja. Nem az fent felsorolt kutatók írták, hanem a közzétett munkáikon alapul.

Tudományos források

Az ezen az oldalon található információk a következő tudományos tanulmányokon és publikációkon alapulnak:

Cytochrome P450 2E1 (CYP2E1) Is the Principal Enzyme Responsible for Urethane Metabolism

Hoffler U., El-Masri H.A., Ghanayem B.I. (2003) – Journal of Pharmacology and Experimental Therapeutics

Tanulmány megtekintése

Kava: From Ethnology to Pharmacology

Yadhu N. Singh (Editor) (2004) – CRC Press

Tanulmány megtekintése
Last updated: 2026. március 18.•New study added